Medivation (MDVN)

85.01 -1.60  -1.85%  May 30, 8:00PM Go Pro
Watch this stock
View Full Chart MDVN Price Chart

Key Stats

Market Cap 3.062B
Revenue Growth 150.4%
Profit Margin 1.19%
Earnings Yield -1.01%
Dividend Yield 0.00%
Earnings Per Share TTM -0.86
PE Ratio
Price / Sales Ratio 37.11
52 Week High 89.46
52 Week Low 14.32
Beta 1.087
View Pro Ratings Details

YCharts Pro Ratings

Go Pro.
Learn More
  • Pro Value Score Go Pro
  • Pro Fundamental Score Go Pro
  • Pro Valuation from Historical Multiples Go Pro

News

May 30 This Biotech Will Have Revenue in 6 Months Fool
May 30 Global Fears and Small Caps: How Much of an Impact? Benzinga
May 30 InPlay: Medivation and Astellas announce initiation of expanded access program for En...
May 30 Medivation, (MDVN), Astellas Pharma to Proceed with EAP for Enzalutamide Street Insider
May 30 Medivation and Astellas Announce Initiation of Expanded Access Program for Enzalutami...
May 29 Is Dendreon's Downgrade Deserved? Fool
May 28 $vvus, $mdvn, $pcyc have done well, but they will explode once the market starts getting some traction again. by lennylex
May 28 $MDVN http://stks.co/40Ko Wait for some sort of pullback or Buy when clears $90 on heavy volume by ACInvestorBlog
May 25 A Forward Look, the Year Ahead - Featured Research on Baidu.com, Inc. (ADR) and Mediv...
May 25 [video] The Next Big Thing in Biotech: ASCO Conference
May 24 $MDVN Insider Sale: $1.1M of stock sold by Lynn Seely on May 22, 2012 http://stks.co/3ywK by MarketBrief
May 24 $MDVN New 52 Week High - Crossed daily highs resistance. by TradeIdeasQuant
May 23 $MDVN http://stks.co/3xrS trend likely to continue in the coming days/weeks, entry on a new high http://stks.co/3xrT by TraderHR

Profile

Exchange: NASDAQGM       Sector: Healthcare       Industry: Biotechnology

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat critically ill patients with serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Its product candidates in clinical development are MDV3100, which is in Phase 3 development for the treatment of advanced prostate cancer, and dimebon (latrepirdine), which is in Phase 3 development for the treatment of Alzheimer's disease and Huntington disease. The company was founded by David T. Hung in September 2003 and is headquartered in San Francisco, California.

1 Year Total Return Performance

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Medivation is up 256.5% over the last year vs S&P 500 Total Return up 2.32%, Dendreon Corporation down 83.60%, and Johnson & Johnson down 3.36%.

  • MDVN Total Returns
  • ^SPXTR Total Returns
  • DNDN Total Returns
  • JNJ Total Returns

Fundamentals

Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.

Income Statement View Statement

Balance Sheet View Statement

Cash Flow Statement View Statement

Get Quote for

Pro Strategies Featuring MDVN

Did Medivation make it into our Pro Portfolio Strategies?

Start your YCharts Pro membership now to find out.

MDVN Charts

Recent Quotes

Symbol Price Chg Chg % Market Cap
MDVN 85.01 -1.60 -1.85% 3.119B
MDU 22.43 -0.41 -1.80% 4.313B
MDTH 7.88 -0.20 -2.48% 164.43M
MDT 36.65 -0.63 -1.69% 38.79B
MDSO 27.76 -0.13 -0.47% 695.30M
MDS 11.50 +0.00 +0.00% 165.72M
MDRX 10.97 -0.24 -2.14% 2.136B
MDR 10.18 -0.72 -6.61% 2.562B
MDP 29.62 +0.04 +0.14% 1.325B
OESX 2.14 +0.07 +3.38% 47.63M
You must be signed in to use watchlists.
Sign In or Register
Create Watchlist from Stock Quotes
Close